Skip to main content

mometasone furoate (Nasonex®)

 

Following non-submission

AWMSG advice

Status: Not endorsed (Statement of Advice)

In the absence of a submission from the holder of the marketing authorisation, mometasone furoate (Nasonex®) cannot be endorsed for use within NHS Wales for use in children aged 3 to 6 years to treat the symptoms of seasonal allergic or perennial rhinitis.

 Statement of Advice (SOA): mometasone furoate (Nasonex) 2894 (PDF, 96Kb)

Medicine details

Medicine name mometasone furoate (Nasonex®)
Formulation 50 micrograms/actuation nasal spray
Reference number 2894
Indication

For use in children aged 3 to 6 years to treat the symptoms of seasonal allergic or perennial rhinitis.

Company Merck Sharp & Dohme Ltd
BNF chapter Ear, nose & oropharynx
Assessment type Non-submission
Status Not endorsed (Statement of Advice)
Ratification by Welsh Government 09/12/2015
Date of issue 10/12/2015
Follow AWTTC: